Skip to main content
SpringerLink
Log in

Drug–Nutrient Interactions Involving Folate

  • Chapter
  • First Online:
Handbook of Drug-Nutrient Interactions

Part of the book series: Nutrition and Health ((NH))

  • 2904 Accesses

Objectives

• Review folate requirements in health and disease.

• Describe the biochemical alterations that occur as a result of folate deficiency.

• Identify risk factors for folate deficiency.

• Delineate practice guidelines for managing potential drug–folate interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Centers for Disease Control and Prevention (CDC). Recommendations for the use of folic acid to reduce the number of cases of spinal bifida and other neural tube defects. MMWR, Recomm Rep 1992;41(RR14):1–7.

    Google Scholar 

  2. Stover PJ. Physiology of folate and vitamin B12 in health and disease. Nutr Rev 2004;62 (6 Pt 2):S3–S12.

    Google Scholar 

  3. Stanger O. Physiology of folic acid in health and disease. Curr Drug Metab 2002;3:211–223.

    CAS  Google Scholar 

  4. Haslam N, Probert CS. An audit of the investigation and treatment of folic acid deficiency. J R Soc Med 1998;91:72–73.

    CAS  Google Scholar 

  5. Carmel R. Folic acid. In: Shils ME, Shike M, Ross AC, et al. eds. Modern Nutrition in Health and Disease, 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.

    Google Scholar 

  6. Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 2006;136:1726S–1730S.

    CAS  Google Scholar 

  7. Ravaglia G, Forti PM, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr 2005;82:636–643.

    CAS  Google Scholar 

  8. Institute of Medicine (IOM). Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 1998:196–305.

    Google Scholar 

  9. Bailey LB. Folate and Vitamin B12 recommended intakes and status in the United States. Nutr Rev 2004;62(6Pt 2):S14–S20.

    Google Scholar 

  10. Pfeiffer CM, Johnson CL, Jain RB, et al. Trends in blood folate and vitamin B12 concentrations in the United States, 1998–2004. Am J Clin Nutr 2007;86:718–727.

    CAS  Google Scholar 

  11. Meshkin B, Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics. Drug Metab Letters 2007;1:55–60.

    CAS  Google Scholar 

  12. Nygard O, Refsum H, Ueland PM, et al. Major lifestyle determinants of plasma homocysteine distribution: the Hordaland Homocysteine Study. Am J Clin Nutr 1998;67:263–270.

    CAS  Google Scholar 

  13. Hatzis CM, Bertsias GK, Scott JM, et al. Dietary and other lifestyle correlates of serum folate concentrations in healthy adult population in Crete, Greece. Nutr J 2006;5:5.

    Google Scholar 

  14. Knight EM, Hutchinson J, Edwards CH, et al. Relationships of serum illicit drug concentrations during pregnancy to maternal nutritional status. J Nutr 1994;124:973S–960S

    CAS  Google Scholar 

  15. Au WY, Tsang SK, Cheung BKL, et al. Cough mixture abuse as a novel cause of folate deficiency: a prospective, community-based, controlled study. Haematologica 2007;92:562–563.

    Google Scholar 

  16. Au WY, Tsang J, Cheng TS, et al. Cough mixture abuse as a novel cause of megaloblastic anemia and peripheral neuropathy. Br J Haemtol 2003;123:956–958.

    CAS  Google Scholar 

  17. Tsang SK, Au WY. Cough mixture abuse in pregnancy, folate deficiency and neural tube defects? Am J Hematol 2005;78:63.

    Google Scholar 

  18. Herbert V. Experimental nutritional folate deficiency in man. Trans Assoc Am Physician 1962;75:307–320.

    CAS  Google Scholar 

  19. American College of Obstetricians and Gynecologists. Clinical Management Guidelines for Obstetrician–Gynecologists. Number 44: neural tube defects. Obstet Gynecol 2003;102:203–213.

    Google Scholar 

  20. 19a.U.S. Preventive Services Task Force. Folic acid for the prevention of neural tube defects: U.S. preventive service task force recommendation statement. Ann Intern Med 2009;150:626–631.

    Google Scholar 

  21. Butterworth CE, Tamura T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353–358.

    CAS  Google Scholar 

  22. Shane B. Folate fortification: enough is enough? Am J Clin Nutr 2003;77:8–9.

    CAS  Google Scholar 

  23. Kelly P, McPartlin J, Goggins M, et al. Unmetabolized folic acid in serum in subjects consuming fortified food and supplements. Am J Clin Nutr 1997;65:1790–1795.

    CAS  Google Scholar 

  24. Lucock M, Yates Z. Folic acid – vitamin and panacea or genetic time bomb? Nat Rev Genet 2005 Mar;6:235–40.

    CAS  Google Scholar 

  25. Ulrich CM, Potter JD. Folate supplementation: too much of a good thing? Cancer Epidemiol Biomarkers Prev 2006;15:189–193.

    Google Scholar 

  26. Mitchell DC, Vilter CF. Hypersensitivity to folic acid. Ann Intern Med 1949;31:1102–1105.

    CAS  Google Scholar 

  27. Woodcliff HJ, Davis RE. Allergy to folic acid. Med J Aust 1966;1:351–352.

    Google Scholar 

  28. Dykewicz MS, Orfan NA, Sun W. In vitro demonstration of IgE antibody to folate-albumin in anaphylaxis from folic acid. J Allergy Clin Immunol 2000;106:386–389.

    CAS  Google Scholar 

  29. Pfab F, Willi R, Albert A, et al. Anaphylactic reaction to folic acid verified by provocational testing. Allergy 2007;62:823–824.

    CAS  Google Scholar 

  30. Smith J, Empson M, Wall C. Recurrent anaphylaxis to synthetic folic acid. Lancet 2007;370:652.

    Google Scholar 

  31. Benchalal M, Yahchouchy-Chouillard E, Fouere S, et al. Anaphylactic shock secondary to intravenous administration of folinic acid: a fist report. Ann Oncology 2002;13:480–481.

    CAS  Google Scholar 

  32. Matherly LH, Hou Z, Deng Y. Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 2007;26:111–128.

    CAS  Google Scholar 

  33. Carmel R, Green R, Rosenblatt DS, et al. Update on cobalamin, folate, and homocysteine. In: Broudy VC, Prchal JT, Tricot GJ, eds. American Society of Hematology Education Program Book. Washington, DC: American Society of Hematology, 2003:62–81.

    Google Scholar 

  34. Botto LD, Yang Q. 5, 10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862–877.

    CAS  Google Scholar 

  35. Robien K, Ulrich CM. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk. Am J Epidemiol 2003;157:751–782.

    Google Scholar 

  36. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111–113.

    CAS  Google Scholar 

  37. Ulrich CM, Robien K, McLeod HL. Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 2003;3:912–920.

    CAS  Google Scholar 

  38. Xu X, Gammon MD, Wetmur JG, et al. A pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users. Am J Clin Nutr 2007;85:1098–1102.

    CAS  Google Scholar 

  39. Fohr IP, Prinz-Langenohl R, Bronstrup A, et al. 5,10 metheylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5 methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 2002;75:275–282.

    CAS  Google Scholar 

  40. deBree A, Verscheuren WMM, Bjorke-Monsen AL, et al. Effect of the methylenetetrahydrofolate reductase 677C?T mutation on the relations among folate intake and plasma folate and homocystiene concentrations in general population samples. Am J Clin Nutr 2003;77:687–693.

    CAS  Google Scholar 

  41. Smulders YM, deMan AM, Stehouwer CD, et al. Trimethoprim and fasting plasma homocysteine. Lancet 1998;352:1827–1828. [Erratum, Lancet, 1999, 353 758.]

    CAS  Google Scholar 

  42. Varela-Moreiras G. Nutritional regulation of homocysteine: effects of drugs. Biomed Pharmacother 2001;55:448–453.

    CAS  Google Scholar 

  43. Dierkes J, Westphal S. Effects of drugs on homocycteine concentrations. Semin Vasc Med 2005;5:124–139.

    Google Scholar 

  44. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002;29(2 Suppl 5):3–7.

    CAS  Google Scholar 

  45. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists and the risk of birth defects. N Engl J Med 2000;343:1608–1614.

    CAS  Google Scholar 

  46. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985;30:145–155.

    CAS  Google Scholar 

  47. Robien K. Folate during antifolate chemotherapy: what we know and do not know. Nutr Clin Pract 2005;20:411–422.

    Google Scholar 

  48. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 2003:21 145–156.

    Google Scholar 

  49. Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. Clin Ther 2005;27:1343–1382.

    CAS  Google Scholar 

  50. Ulrich CM, Robien K. McLoed. Cancer pharmacogenetics: polymorphisms, pathways, and beyond. Nat Rec Cancer 2003;3:912–920

    CAS  Google Scholar 

  51. Hutchinson E. Working towards tailored therapy for cancer. Lancet 2001;357:1508.

    CAS  Google Scholar 

  52. Malinow MR, Duell PB, Williams MA, Kruger WD, Evans AA, Anderson PH, et al. Short-term folic acid supplementation induces variable and paradoxical changes in plasma homocysteine concentrations. Lipids 2001;S27–S32.

    Google Scholar 

  53. Lewis DP, VanDyke DC, Willhite LA, Stumbo PJ, Berg MJ. Phenytoin-folic acid interaction. Ann Pharmacother 1995;29:726–735.

    CAS  Google Scholar 

  54. Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M. Phenytoin-folic acid interaction: a lesson to be learned. Clin Neurpharmacol 22(5):268–272, 1999.

    CAS  Google Scholar 

  55. Steinweg DL, Bentley M. Seizures following reduction in phenytoin level after orally administered folic acid. Neurology 2005;64:1982.

    Google Scholar 

  56. Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998;25 :36–43.

    CAS  Google Scholar 

  57. VanEde AE, Laan RF, Rood JM., Huizinger TW, van de Laar MA, van Deren CJ. Effect of folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2001;44:1515–1524.

    CAS  Google Scholar 

  58. Griffith SM, Fisher J, Clarke S. Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? Rheumatology 2000;39:1102–1109.

    CAS  Google Scholar 

  59. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management and care of the pregnant women with epilepsy. Neurology 1992;42:149–160.

    CAS  Google Scholar 

  60. Penovich PE, Eck KE, Economou VV. Recommendations for the care of women with epilepsy. Cleveland Clinic J Med 2004;71(suppl 2):S49–S57.

    Google Scholar 

  61. American Academy of Neurology. Practice parameter: Management issues for women with epilepsy. Report of the Quality Standard Subcommittee of the American Academy of Neurology. Neurology 1998;51:944–948

    Google Scholar 

  62. Ogawa Y, Kaneko S, Otani K, et al. Serum folic acid levels in epileptic mothers and their relationship to congenital malformations. Epilepsy Res 1991;8:75.

    CAS  Google Scholar 

  63. American College of Obstetric and Gynecologic Physicians. Seizure disorders in pregnancy. ACOG Educ Bull 1996;231:1–13.

    Google Scholar 

  64. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005;46(suppl 9):117–124

    Google Scholar 

  65. Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ. Drug and environmental factors associated with adverse pregnancy outcomes part III: folic acid: pharmacology, therapeutic recommendations, and economics. Ann Pharmacother 1998;32:1087–1095.

    CAS  Google Scholar 

  66. Morrell MJ. Folic acid and epilepsy. Epilepsy Currents 2002;2:31–34.

    Google Scholar 

  67. McAuley JW, Anderson GD. Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. Clin Pharmacokinet 2002;41:559–579.

    CAS  Google Scholar 

  68. Yerby MS. Clinical care of pregnant women with epilepsy: neural defects and folic acid supplementation. Epilepsia 2003;44:33–40.

    CAS  Google Scholar 

  69. Morrell MJ. Guidelines for the care of women with epilepsy. Management of epilepsy: consensus conference on current clinical practice. Neurology 1998;51:S21–S27.

    CAS  Google Scholar 

  70. Pschirrer ER. Seizure disorders in pregnancy. Obst Gyn Clin North Am 2004;31:373–384.

    Google Scholar 

  71. Genton P, Semah F, Trinka E. Valproic acid in epilepsy: pregnancy related issues. Drug Safety 2006;29:1–21.

    CAS  Google Scholar 

  72. Kishi T, Fujita N, Eguchi T, Ueda K. Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 1997;145:109–112.

    CAS  Google Scholar 

  73. Robien K, Schubert MM, Yasui Y, et al. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of graft-versus-host-disease, or relapse following hematopoietic transplantation. Bone Marrow Transplant 2006;37:687–692.

    CAS  Google Scholar 

  74. Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004;43:267–271.

    CAS  Google Scholar 

  75. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005;53:652–659.

    Google Scholar 

  76. VanEde AE, Laan RF, Blom, HJ, Boers GH, Haagsma CJ, Thomas CM. Homocycteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002;41:658–665.

    CAS  Google Scholar 

  77. VanEde, AE, Laan RF, Rood, MJ, et al: effect of folic acid or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum 2001;44(7):1515–1524.

    CAS  Google Scholar 

  78. Ortiz Z, Shea B, Suarez-Alamazor ME, Moher D, Wells G, Tugwell P, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. (Cochrane Review). In The Cochrane Library, Issue 4. Oxford: Update Software, 2002.

    Google Scholar 

  79. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996;39:723–731.

    Google Scholar 

  80. Griffith SM, Fischer J, Clarke S, et al. Do patients with rheumatoid arthritis established on methotrexate 5 mg daily need to continue folic acid supplements long term? Rheumatology 2000;39:11-2-1109.

    Google Scholar 

  81. Joyce DA, Will RK, Hoffman DM, Laing B, Blackbourn SJ. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991;50:913–914.

    CAS  Google Scholar 

  82. Enderson GKM, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. Scand J Rheumatol 2001;30:129–134.

    Google Scholar 

  83. Hoekstra M, van Ede AE, Haagsma CJ, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423–426.

    CAS  Google Scholar 

  84. Stein TA, Burns GP, Bailey B, Citron ML. l. 5-fluorouracil pharmacokinetics in patients with metastatic colorectal carcinoma after high-dose leucovorin. Cancer Invest 1994;12:375–378.

    CAS  Google Scholar 

  85. Clippe C, Feeyer G, Milano G, et al. Lethal toxicity of capecitabine due to abusive folic acid prescription. Clin Oncol (R Coll Radiol) 2003:15;299–3000.

    Google Scholar 

  86. Richards FO, Kovacs JA, Luft BJ. Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21:S49–S56.

    Google Scholar 

  87. Helmer RE. Hazards of folinic acid with pyrimethamine and sulfadiazine. Ann Int Med 1975;82:124–125.

    Google Scholar 

  88. Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcomes. J Infect Dis 1996;173:1294–1295.

    Google Scholar 

  89. Tong MJ, Strickland GT, Votteri BA, Gunning JJ. Supplemental folates in the therapy of Plasmodium falciparum malaria. JAMA 1970;214:2330–2333.

    CAS  Google Scholar 

  90. Peters PJ, Thigpen MC, Parise ME, et al. Safety and toxicity of sulfadoxine/primethamine. Implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug Safety 2007;30:481–501.

    CAS  Google Scholar 

  91. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death. J Infect Dis 1994;170:912–917.

    CAS  Google Scholar 

  92. Coppen A, Swade C, Jones SA, Armstrong RA, Blair JA, Leeming RJ. Depression and tetrahydrobiopterin: the folate connection. J Affect Disord 1989;16:103–107.

    CAS  Google Scholar 

  93. Coppen A, Bolander-Gouille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005;19:59–65.

    CAS  Google Scholar 

  94. Abou-Saleh MT, Coppen A. Folic acid and the treatment of depression. J Pyschosom Res 2006;61:285–287.

    Google Scholar 

  95. Papakostas GI, Petersen T, Mischoulon D, et al. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004;65:1096–1098.

    CAS  Google Scholar 

  96. Coppen A. Baily J. Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial. J Affect Disord 2000;60:121–130.

    CAS  Google Scholar 

  97. Morrow LE, Grimsely EW. Long-term diuretic therapy in hypertensive patients: effects on serum homocysteine, vitamin B6, vitamin B12, and red blood cell folate concentrations. South Med J 1999;92:866–870.

    CAS  Google Scholar 

  98. Sidholm MB, Velez MR. Monitoring the effect of triamterene and hydrochlorothiazide on dehydrofolate reductase activity using a new spectrophotometric method. J Pharm Biomed Anal 1989;7:1551–1557.

    Google Scholar 

  99. Montalar M. Nalda-Molina R, Rodriguez-Ibanez M, et al. Kinetic modeling of triamterene intestinal absorption and its inhibition by folic acid and methotrexate. J Drug Targeting 2003;11:215–223.

    CAS  Google Scholar 

  100. Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier. Implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004;7:2130–2139.

    Google Scholar 

  101. Krogh JM, Ekelund S, Svendsen L. Folate and Homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest 1996;56:421–429.

    Google Scholar 

  102. Smith CL, Powell KR. Review of sulfonamides and trimethoprim. Pediatr Rev 2000;21:368–371.

    CAS  Google Scholar 

  103. Graham TO, Kandil HM. Nutritional factors in inflammatory bowel disease. Gastroenterol Clin North Am 2002;31:203–218.

    Google Scholar 

  104. Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol Clin North Am 2003;32:323–340.

    Google Scholar 

  105. Pironi L, Cornia GL, Ursitti MA, Dallasta MA, Miniero R, Fasano F, et al. Evaluation of oral administration of folic and folinic acid to prevent folate deficiency in patients with inflammatory bowel disease treated with salicylazosulfapyridine. Int J Clin Pharmacol Res 1988;8:143–8.

    CAS  Google Scholar 

  106. Logan EC, Williamson LM, Ryrie DR. Sulphasalazine associated pancytopenia may be caused by acute folate deficiency. Gut 1986;27:868–72.

    CAS  Google Scholar 

  107. Baggott JE, Morgan SL, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992;282:197–202.

    CAS  Google Scholar 

  108. Russell DM, Dutta SK, Rosenberg IH, Giovetti AC. Impairment of folic acid by oral pancreatic extracts. Dig Dis Sci 1980;25:369–373.

    CAS  Google Scholar 

  109. Leonard JP, Desager JP, Beckers C, Harvengt C. In vitro binding of various biological substances by two hypocholesterolaemic resins. Arzneimittelforschung 1979;29:979–981.

    CAS  Google Scholar 

  110. West RJ, Lloyd JK. The effect of cholestyramine on intestinal absorption. Gut 1975;16:93–98.

    CAS  Google Scholar 

  111. Cholestyramine Resin. Drug Information. Merck Manual (online) Available at http://www.merck.com/mmpe/print/lexicomp/cholestyramine%20resin.html. Accessed May 2008.

  112. Wulffele MG, Kooy A, Lehert P, et al. Effects of short term treatment with metformin on serum concentrations of homocysteine, folate, and vitamin B12 in type 2 diabetes mellitus: a randomized placebo-controlled trial. J Intern Med 2003;254:455–463.

    CAS  Google Scholar 

  113. Sahin M, Tutuncu NB, Ertugrul D, et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications 2007;21:118–123.

    Google Scholar 

  114. Aarsand AK, Carlen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 1998;244:169–174.

    CAS  Google Scholar 

  115. Centers for Disease Control and Prevention. Folic Acid: PHS Recommendations. Issued July 26, 2005. Available at: http://www.cdc.gov/ncbddd/folicacid/health_recomm.htm. Accessed May 2008.

Download references

Author information

Authors and Affiliations

  1. Department of Nursing, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Patricia Worthington RN, MSN, CNSN

  2. Department of Pharmacy Services, Thomas Jefferson University Hospital, Philadelphia, PA, USA

    Leslie Schechter PHARMD

Authors
  1. Patricia Worthington RN, MSN, CNSN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leslie Schechter PHARMD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Nursing, University of Pennsylvania, Guardian Dr. 420, Philadelphia, 19104, U.S.A.

    Joseph I. Boullata

  2. Dept. Surgery, Temple University Hospital, N. Broad St. 3401, Philadelphia, 19140, U.S.A.

    Vincent T. Armenti

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Worthington, P., Schechter, L. (2009). Drug–Nutrient Interactions Involving Folate. In: Boullata, J., Armenti, V. (eds) Handbook of Drug-Nutrient Interactions. Nutrition and Health. Humana Press. https://doi.org/10.1007/978-1-60327-362-6_18

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-362-6_18

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-363-3

  • Online ISBN: 978-1-60327-362-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation